Topas is open to various types of collaboration. The Company plans to partner its proprietary programs at the clinical or pre-clinical stage on an option or a classical licensing basis with biotech or pharmaceutical companies. Topas is also interested in pre-clinical co-development agreements with biotech or academia that have complementary know-how and capabilities. Furthermore, Topas remains open to collaborating with pharmaceutical and biotech companies on selected indications proposed by the respective partner.

Upcoming Events

Deutsche Biotechnologietage

April 18 & 19, 2018

Antigen-Specific Immune Tolerance Drug Development

April 24-26, 2018